Breaking News, Promotions & Moves

Allergen Expands Management

Drs. Rozenman and Holfinger to oversee Phase III trial of lead product, AR 101

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mary Rozenman, Ph.D., has been appointed senior vice president, corporate and commercial development at Allergen Research Corp. (ARC), and Mike Holfinger, Ph.D., was named vice president, manufacturing.   Dr. Rozenman and Dr. Holfinger will fill key functions as ARC prepares for its upcoming Phase III trial of its lead product, AR 101, a peanut protein formulation for treating peanut allergy via characterized oral desensitization immunotherapy (CODIT). The company also plans to initiate clinical...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters